Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

NCT07535359 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

SCLC
Extensive-stage Small Cell Lung Cancer

Interventions

DRUG: Ifinatamab Deruxtecan

Sponsor

Daiichi Sankyo

Collaborators

[object Object]